Navigation Links
Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Date:8/19/2007

KING OF PRUSSIA, Pa., Aug. 2 /PRNewswire/ -- Cytokine PharmaSciences, Inc. (CPSI) today revealed that recent experiments with its small-molecule MIF inhibitors showed oral efficacy in animal models. Based on these results, the Company announced that it is advancing one of these compounds into preclinical development.

Macrophage Migration Inhibitory Factor, or MIF, is linked to many conditions, including arthritis, asthma, cancer, sepsis, inflammatory bowel disease and various infections and autoimmune disorders. Neutralization of MIF biological activity has been shown to have a protective effect against these diseases. CPSI has an extensive patent portfolio focused on MIF, covering various methods for neutralization, including small molecules. These compounds were recently shown to be effective in animal models of multiple sclerosis (MS) and arthritis when administered orally.

The MS animal experiments were conducted in the laboratories of Dr. Abhay Satoskar and Dr. Caroline C. Whitacre, both of Ohio State University in Columbus, OH. Dr. Satoskar stated: "The therapeutic efficacy of these compounds was impressive with no outward signs of toxicity. These findings indicate that small-molecule MIF inhibitors are viable drug candidates for treating other autoimmune and inflammatory diseases in which MIF has been identified as a pathogenic factor." Dr. Whitacre adds: "The inhibitors were especially effective in treating disease that had already started, which is traditionally the most difficult hurdle for a new therapy. We are very encouraged by these results."

The arthritis experiments were conducted under the guidance of Drs. Thais M. Sielecki and Vidal F. de la Cruz of Cytokine PharmaSciences, Inc. Dr. Sielecki observed: "We are encouraged to have a small molecule MIF inhibitor that is orally active. MIF is an important target in many diseases and an oral treatment is a definite advantage." Dr. Sielecki will present the MS and arthritis result
'/>"/>

SOURCE Cytokine PharmaSciences, Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related medicine technology :

1. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
2. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
3. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
4. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
5. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
6. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
7. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
8. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
9. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Kalifornien, 28. August 2014 ... Start der Patientenrekrutierung für eine IDE-Pivot-Studie ... zur Beurteilung der Sicherheit und Wirksamkeit ... Aneurysmen („WEB") bekanntgegeben. Adam Arthur, MD, Dozent ... of Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der ...
(Date:8/28/2014)... ALISO VIEJO, Calif. , Aug. 28, 2014 ... has initiated patient enrollment in an Investigational Device ... and effectiveness of the WEB™ Aneurysm Embolization System ... University of Tennessee Department of Neurosurgery/Semmes-Murphey Clinic and ... first four patients in the study, treating them with ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
Breaking Medicine Technology:Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3
... PARK, Ill., Oct. 20 Abbott has,received a ... Drug,Administration (FDA) for its New Drug Application (NDA) ... is,evaluating the FDA Complete Response Letter, will discuss ... update when appropriate., Abbott is seeking the ...
... Corporation,(Nasdaq: ALUS ), the worldwide leader in ... scientific,posters featuring both patient cases and laboratory research ... presented this week at the American,Society of Anesthesiologists ... Dr. Arie Blitz, Director of Heart Transplantation and ...
Cached Medicine Technology:Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 2Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 3
(Date:8/28/2014)... greater amounts of yellow pigment in your eyes could ... conditions, a new study reports. In a laboratory ... order to test the distance vision of people with ... in their eyes. The volunteers had widely varying ... nutrients lutein and zeaxanthin, according to the researchers, led ...
(Date:8/28/2014)... GreenRushReview.com, a website dedicated to ... “Video” section located at http://www.greenrushreview.com/category/videos/ , which ... cannabis companies in video format. In the site’s ... news clips, interviews, and other short videos discussing ... the videos can also be found on the ...
(Date:8/28/2014)... Alexandria, VA (PRWEB) August 28, 2014 ... Foundation) will interview Stephen Isaacs, the chairperson, president and ... the Foundation’s Meet the Mesothelioma Experts live ... Foundation’s executive director and mesothelioma expert nurse practitioner, ... the interview will be Aduro BioTech’s experimental therapy for ...
(Date:8/28/2014)... PreDiabetes Centers, the nation’s top provider of prediabetes ... help clients and online readers send out summer healthfully ... Ashley developed variations of Roasted Veggie Pizza , ... PreDiabetes Centers Roasted Veggie Pizza recipe is made with ... a cheese substitute–ideal for people who are lactose intolerant ...
(Date:8/28/2014)... 2014 veEDIS Clinical Systems, LLC ... System (EDIS), in Lawrence Medical Center, located in ... to document patient care, veEDIS is a key ... well as the authorized, confidential exchange of patient ... veEDIS technology, designed in accordance with clinical workflows ...
Breaking Medicine News(10 mins):Health News:Eye Pigment May Help Vision in Hazy Conditions 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 3Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 2Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 3Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 3
... COPD or chronic obstructive pulmonary disease is a ... // and is associated with severe emphysema or ... can reduce the mortality rate and number of ... study conducted by researchers from the University of ...
... say transmission of genital herpes to others is the ... study shows //the drug valacyclovir may significantly reduce the ... more than 1,400 heterosexual couples. In each case, one ... other was susceptible to the virus. Type 2 herpes ...
... change the way doctors treat certain prostate cancer patients.The ... cancer patient are grade, PSA level and pathologic stage. ... the Gleason grading system or a Gleason score (GS). ... cancer is seven. In a new study, researchers look ...
... A new study shows the drug valacyclovir may significantly ... more than 1,400 heterosexual couples. In each case, one ... other was susceptible to the virus. Type 2 herpes ... contagious. Participants with herpes were given ...
... since it interferes with eating and drinking. Children are ... the importance of maintaining// their normal fluid intake despite ... tonsillectomy procedure using less energy than the standard electrocautery ... ,During a tonsillectomy using the electrocautery method, a ...
... by researchers say it is a misconception to believe ... housebound people.// ,Researchers examined 150 children and ... vitamin D. Among the participants, all African-American, East African, ... as were all patients younger than 30. Five patients ...
Cached Medicine News:
Antigenic Free Protein S, ELISA Method...
... Assay for the Quantitative ... Protein S level based ... Va Inhibition by STA© ... free of Protein S; ...
Colorimetric Assay of Protein C Activity by STA© Analyzers. Highly purified extract of Agkistrodon c. contortrix venom for specific activation of protein C, with an activator selected specially ...
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Medicine Products: